Stem Cell Therapy for Heart Failure: An Unfulfilled Promise? | Stem Cell Transplantation | JAMA | JAMA Network
[Skip to Navigation]
Sign In
Editor's Note
March 26, 2019

Stem Cell Therapy for Heart Failure: An Unfulfilled Promise?

JAMA. 2019;321(12):1186-1187. doi:10.1001/jama.2019.2617

With modern, guideline-directed therapy,1 which includes angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), β-receptor blockers, mineralocorticoid receptor blockers, and angiotensin receptor neprilysin inhibitors, up to 40% of patients with dilated cardiomyopathy (heart failure with reduced ejection fraction) may experience a return of left ventricular ejection fraction (LVEF) and ventricular geometry to normal.2 This encouraging result follows a progressive series of important advances in research on heart failure therapies having diverse mechanisms of action. Until recently, however, it was uncertain if such patients had actually recovered from heart failure with reduced ejection fraction or if they had only entered a state of remission.

The TRED-HF trial has brought clarity to this important question.3 In this study, patients with heart failure with reduced ejection fraction and complete reversal of left ventricular dysfunction were randomized to have their heart failure medications withdrawn or maintained. Within just 8 weeks, 44% of the patients in the medication withdrawal group relapsed, as reflected by a reduction in LVEF, an increase in left ventricular end-diastolic volume, and an increase in cardiac biomarkers. These results clearly indicated that even after years of productive research on the development of advanced medical therapies, it is not yet possible to reverse the underlying pathological process.

Consequently, there is an important need for therapies to durably restore ventricular function, and one approach has focused on stem cell–based therapies.4 Stem cells, which are derived from the bone marrow or umbilical cord blood, have been infused into the coronary arteries or injected directly into the myocardium. The original hypothesis was that stem cells would engraft in the myocardium and replace damaged cardiomyocytes. Subsequent research has suggested that stem cells probably do not differentiate into functional cardiomyocytes, but as an alternative hypothesis, it was hoped that they might have paracrine effects that would benefit myocardial function.

However, the weight of the evidence to date indicates that any clinical benefit resulting from stem cell therapy for heart failure with reduced ejection fraction has been small and inconsistent. The study by Yau et al5 in this issue of JAMA is yet another example of a negative study in a largely disappointing body of cell-based research. The investigators injected bone marrow–derived mesenchymal precursor cells into the myocardium of patients who were receiving LVAD support for advanced heart failure—106 patients received mesenchymal stem cells and 53 received sham injections—and found no benefit on the ability to wean the patients from LVAD support at 6 months. This study is important because it provides further evidence that mesenchymal precursor cells injected into the myocardium may not be the answer to the challenging problem of advanced heart failure due to dilated cardiomyopathy.

Given the generally negative results of cell-based studies to date, a European Society of Cardiology Working Group concluded that the promise of cell therapy has not yet been fulfilled.6 The recent disclosure that the research of one of the pioneers of cell-based therapy, Piero Anversa, was largely fraudulent, has tainted this field of investigation.7

Astonishingly, despite the lack of an evidence base, a recent survey concluded that there are at least 570 businesses in the United States that offer stem cell therapy, at least 61 of which market to patients with heart failure.8 Since stem cell therapy for heart failure is not approved by the US Food and Drug Administration, it appears that further regulatory action needs to be directed to these unauthorized activities.

To what extent should funding bodies continue to invest research dollars in stem cell therapy for heart failure? Although a note of optimism was recently offered,4 based on the unimpressive results to date, it will be even more important to be parsimonious about investments in stem cell therapy for heart failure unless new ideas and novel approaches open fresh avenues for potential success.

Back to top
Article Information

Corresponding Author: Gregory Curfman, MD, Deputy Editor, JAMA, 330 N Wabash Ave, Chicago, IL 60611 (gregory.curfman@jamanetwork.org).

Conflict of Interest Disclosures: None reported.

References
1.
Yancy  CW, Jessup  M, Bozkurt  B,  et al; WRITING COMMITTEE MEMBERS.  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.  Circulation. 2016;134(13):e282-e293.PubMedGoogle Scholar
2.
Nijst  P, Martens  P, Mullens  W.  Heart failure with myocardial recovery—the patient whose heart failure has improved: what next?  Prog Cardiovasc Dis. 2017;60(2):226-236. doi:10.1016/j.pcad.2017.05.009PubMedGoogle ScholarCrossref
3.
Halliday  BP, Wassall  R, Lota  AS,  et al.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.  Lancet. 2019;393(10166):61-73. doi:10.1016/S0140-6736(18)32484-XPubMedGoogle ScholarCrossref
4.
Braunwald  E.  Cell-based therapy in cardiac regeneration: an overview.  Circ Res. 2018;123(2):132-137. doi:10.1161/CIRCRESAHA.118.313484PubMedGoogle ScholarCrossref
5.
Yau  TA, Pagani  FD, Mancini  DM,  et al; Cardiothoracic Surgical Trials Network.  Effect of intramyocardial injection of mesenchymal precursor cells on successful temporary weaning from left ventricular assist device support among patients with advanced heart failure: a randomized clinical trial  [published online March 26, 2019].  JAMA. doi:10.1001/jama.2019.2341Google Scholar
6.
Madonna  R, Van Laake  LW, Davidson  SM,  et al.  Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.  Eur Heart J. 2016;37(23):1789-1798. doi:10.1093/eurheartj/ehw113PubMedGoogle ScholarCrossref
7.
Retraction Watch. Anversa cardiac stem cell lab earns 13 retractions. https://retractionwatch.com/2018/12/13/anversa-cardiac-stem-cell-lab-earns-13-retractions. Posted December 13, 2018. Accessed March 1, 2019.
8.
Goff  ZD, Kichura  AB, Chibnall  JT, Hauptman  PJ.  A survey of unregulated direct-to-consumer treatment centers providing stem cells for patients with heart failure.  JAMA Intern Med. 2017;177(9):1387-1388. doi:10.1001/jamainternmed.2017.2988PubMedGoogle ScholarCrossref
×